Rhumbline Advisers grew its stake in shares of Emergent Biosolutions Inc (NYSE:EBS) by 16.1% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 82,228 shares of the biopharmaceutical company’s stock after acquiring an additional 11,399 shares during the period. Rhumbline Advisers owned about 0.17% of Emergent Biosolutions worth $3,821,000 at the end of the most recent quarter.
Other institutional investors also recently bought and sold shares of the company. Prudential Financial Inc. raised its stake in shares of Emergent Biosolutions by 3.6% during the third quarter. Prudential Financial Inc. now owns 75,378 shares of the biopharmaceutical company’s stock valued at $3,049,000 after acquiring an additional 2,618 shares in the last quarter. Rice Hall James & Associates LLC increased its holdings in Emergent Biosolutions by 19.6% during the fourth quarter. Rice Hall James & Associates LLC now owns 769,096 shares of the biopharmaceutical company’s stock valued at $35,740,000 after buying an additional 126,069 shares during the period. Macquarie Group Ltd. increased its holdings in Emergent Biosolutions by 60.1% during the third quarter. Macquarie Group Ltd. now owns 41,573 shares of the biopharmaceutical company’s stock valued at $1,681,000 after buying an additional 15,604 shares during the period. First Quadrant L P CA increased its holdings in Emergent Biosolutions by 217.5% during the fourth quarter. First Quadrant L P CA now owns 12,308 shares of the biopharmaceutical company’s stock valued at $572,000 after buying an additional 8,431 shares during the period. Finally, LSV Asset Management increased its holdings in Emergent Biosolutions by 13.9% during the fourth quarter. LSV Asset Management now owns 746,518 shares of the biopharmaceutical company’s stock valued at $34,690,000 after buying an additional 90,971 shares during the period. 81.58% of the stock is owned by hedge funds and other institutional investors.
Emergent Biosolutions Inc (NYSE:EBS) opened at $52.84 on Wednesday. The stock has a market cap of $2,599.95, a P/E ratio of 31.27, a P/E/G ratio of 1.02 and a beta of 1.26. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.42 and a current ratio of 4.85. Emergent Biosolutions Inc has a 1-year low of $27.94 and a 1-year high of $53.50.
In other Emergent Biosolutions news, EVP Adam Havey sold 5,842 shares of Emergent Biosolutions stock in a transaction on Monday, March 12th. The shares were sold at an average price of $52.82, for a total value of $308,574.44. Following the transaction, the executive vice president now directly owns 35,756 shares of the company’s stock, valued at $1,888,631.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Daniel Abdun-Nabi sold 21,906 shares of Emergent Biosolutions stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $47.91, for a total transaction of $1,049,516.46. Following the completion of the transaction, the chief executive officer now directly owns 226,040 shares in the company, valued at $10,829,576.40. The disclosure for this sale can be found here. Insiders sold 34,798 shares of company stock worth $1,714,330 over the last ninety days. Corporate insiders own 16.50% of the company’s stock.
Several equities analysts recently issued reports on the stock. Goldman Sachs Group assumed coverage on shares of Emergent Biosolutions in a report on Wednesday, January 24th. They set a “neutral” rating and a $55.00 price objective on the stock. Singular Research lifted their price objective on shares of Emergent Biosolutions from $45.00 to $60.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. ValuEngine raised shares of Emergent Biosolutions from a “hold” rating to a “buy” rating in a report on Thursday, March 1st. Zacks Investment Research lowered shares of Emergent Biosolutions from a “hold” rating to a “sell” rating in a report on Monday, February 26th. Finally, Chardan Capital lifted their price objective on shares of Emergent Biosolutions from $47.00 to $53.00 and gave the company a “buy” rating in a report on Tuesday, January 16th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $52.80.
TRADEMARK VIOLATION NOTICE: “Emergent Biosolutions Inc (EBS) Shares Bought by Rhumbline Advisers” was posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.americanbankingnews.com/2018/03/14/emergent-biosolutions-inc-ebs-shares-bought-by-rhumbline-advisers.html.
About Emergent Biosolutions
Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).
Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions Inc (NYSE:EBS).
Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.